A WHO listing would allow Novavax to ship to multiple developing nations that rely on WHO guidance for their regulatory decisions. It expects to file for regulatory authorization in the United States and European Union in the fourth quarter of 2021. Novavax’s COVID-19 vaccine production ramp-up has been fraught with delays and it is unclear how many Novavax shots will be available for the COVAX facility this year. Novavax said in August it was aiming to produce 100 million shots monthly by the end of the third quarter. Early studies suggest Novavax is effective at protecting against the contagious Delta variant of COVID-19, which has become dominant in many countries.

Source: MetroXpress September 23, 2021 13:42 UTC